

1 **TITLE:** PRESCRIBING PRACTICES AND CLINICAL IMPACT OF NEXT GENERATION
2 SEQUENCING IN ROUTINE PRACTICE IN SOLID TUMORS – REAL WORLD
3 EXPERIENCE IN LMIC

4 **SHORT TITLE:**
5 PRESCRIBING PRACTICES AND CLINICAL IMPACT OF NGS IN SOLID TUMORS:
6 REAL-WORLD LMIC EXPERIENCE

7
8 **AUTHOR'S NAME:**

9
10 ADEEBA ZAKI¹
11 NIDA E ZEHRA¹
12 AQSA SOHAIL¹
13 ZEESHAN ANSAR¹
14 MUNIRA MOOSAJEE¹

15
16 ¹DEPARTMENT OF ONCOLOGY, THE AGA KHAN UNIVERSITY HOSPITAL, KARACHI,
17 PAKISTAN

18
19 **CORRESPONDING AUTHOR:**

20 EMAIL: adeeba.zaki@aku.edu

21
22
23 **AUTHORS CONTRIBUTION:**

24 ALL AUTHORS CONTRIBUTED EQUALLY TO THIS WORK

25 **Abstract**

26 Molecular characterization of disease is essential for precision medicine due to novel predictive
27 biomarkers. Multiple next-generation sequencing (NGS) platforms are available, but their
28 expense and clinical utility vary. Even if a targetable mutation is detected, corresponding drugs
29 may not be available or affordable. No prior studies in Pakistan have focused on integrating NGS
30 results into patient care to assist with therapeutic decision-making and survival outcomes.

31 This retrospective study aimed to evaluate the molecular profiling and therapeutic implications
32 of NGS testing across solid tumors. It included all patients with histologically proven
33 malignancy (metastatic or non-metastatic) who had NGS analysis at Aga Khan University
34 Hospital (AKUH) from June 1, 2020, to June 1, 2023. Foundation One was the NGS platform
35 used. From 2020 to 2023, 192 patients underwent NGS. The majority were male (55.2%) and
36 aged over 50 years (71.9%). The most common indications for NGS were carcinoma of unknown
37 primary (CUP) and lung cancers, representing 26% and 25% respectively, followed by colon
38 (9%) and breast cancers (8%). Most patients had metastatic disease (98.4%). Common mutations
39 in lung cancer were EGFR (16.3%) and KRAS G12C (14.3%). In unknown primary, breast, and
40 colon cancers, the most common mutations were BRAF (8%), PIK3CA (18%), and KRAS
41 (42.1%), respectively. Microsatellite instability (MSI) testing was performed in 95% of patients,
42 with 6% being MSI high. Actionable alterations were detected in 31.8% of patients, but only
43 17.2% received genotype-matched treatment, mostly as a first-line treatment for lung cancer. The
44 primary barriers were drug availability and affordability.

45 Our results show that the implementation of NGS analysis supports clinical decision making.
46 However, these results were applicable to a small percentage of patients. For better compliance
47 and applicability, drug availability and cost of treatment needs to be addressed
48 Keywords: Next generation sequencing, lung cancer, mutation, drug.

49 **Introduction**

50 Cancer is a heterogenous disease. Presence of subpopulation of tumour cells with distinct
51 genotype and phenotype leads to divergent biological behavior within a primary tumor and its
52 metastases, or between tumors of the same histopathological subtype [1]. Genetic variations in
53 both the cancer and inherited genomes are informative for hereditary cancer risk, prognosis, and
54 treatment strategies. Given the increasing number of potential targets for cancer therapies, novel
55 applications have been developed that provide information about the tumour genome to guide
56 therapeutic selection. The application of genetic information to assist with the clinical management
57 of patients with cancer is rapidly expanding into routine care [2].

58 There are numerous genetic testing platforms that can guide cancer care from single gene testing
59 by PCR (polymerase chain reaction) or FISH (Fluorescence in situ hybridization) to
60 comprehensive next generation sequencing. Next generation sequencing (NGS) allows rapid
61 simultaneous sequencing of DNA or RNA samples with a higher sensitivity and provides
62 prognostic information on sensitivity or resistance to drugs [3]. Sequencing applications, both
63 genome-wide and targeted, are revealing complex mutational signatures associated with different
64 types of cancers that are now driving both research and therapeutic decisions [4].

65 Studies have evaluated the decision impact of molecular profiling on treatment and their effect on
66 overall survival [5].

67 Studies have evaluated the cost and impact of NGS use at national level on treatment modification
68 and survival [6]. Jones et al. report a statistically significant difference in survival for patients who
69 showed actionable alterations with subsequent targeted therapy in comparison with patients who,
70 despite showing actionable alterations, did not receive targeted therapy and patients who did not
71 show any actionable alterations on NGS testing in gynecological malignancies [7]. In advanced
72 breast cancer clinical application of NGS, real world data revealed that only 4.7% of patients
73 received molecular guided therapy [8].

74 In resource limited countries, routine use of NGS testing is not possible due to cost and availability
75 of testing facility and subsequent drugs. Therefore, we felt that it was essential to evaluate the
76 prescribing practices of NGS in solid malignancies with a focus on the clinical impact of NGS
77 results in patient care to assist with therapeutic decision making. To our knowledge this is the first
78 study evaluating molecular profiling and its therapeutic implication across solid tumors in Pakistan

79 **Material and Methods**

80 **Patients and sample**

81 For this retrospective observational study, all the patients with histologically proven malignancy
82 in whom tumor genomic profiling test ordered from June 2020 till June 2023 were included. There
83 were no limitations for tumor type, treatment line, metastatic vs non- metastatic disease,

84 performance status or organ function. Patients were tested with either Foundation One CDx test,
85 in house targeted hotspot panel (limited gene testing) via PCR or FISH and/ or Microsatellite
86 instability (MSI) testing by PCR. Foundation One CDx, sequences genes from solid tumor tissue
87 sample and reporting the detected alteration (mutation, amplification, deletion, fusion and also
88 tumor mutational burden) along with suggested targeted therapies against each detected alteration.

89 For this retrospective study, the need for individual patient consent was waived by the ethics
90 committee due to the use of de-identified data. All data were anonymized to ensure confidentiality
91 and privacy. As the study involved the analysis of previously collected data, the ethics committee
92 waived the requirement for obtaining new written or verbal consent from participants. When the
93 genomic profiling tests were initially ordered, patients provided informed written consent to have
94 data from their medical records used in research. The study protocol, including the waiver of
95 consent, was reviewed and approved by the ethics committee of The Aga Khan University and
96 considered under exempted study, ensuring that all ethical considerations were addressed.

97 **Statistical Analysis:**

98 Data was analyzed using STATA 16.0. Mean and Standard Deviation or median and intra quartile
99 range (IQR) were calculated for quantitative continuous variables based on the normality of the
100 variables. Frequency and percentages were calculated for categorical variables. Confounders were
101 controlled through stratification; post stratification Chi-square test was applied. Cox proportional
102 hazard regression was used for multivariable analysis to determine the influence of the following
103 variables: matched and nonmatched treatment given before and after NGS analysis, line of

104 treatment at NGS analysis on survival for the total population. A p-value of less than and equal to
105 0.05 was considered as statistically significant.

106 **Results:**

107 367 patients underwent genomic profiling from June 2020 to June 2023 at the Aga Khan University
108 Hospital. Clinical and demographic characteristics of patients.

109 192 patients underwent genomic (Next generation sequencing) testing via Foundation One CDx
110 panel (FMI). 13 had limited targeted hotspot testing and 162 had MSI testing alone. Majority were
111 male (58.8%) while 41% were female. On age stratification, FMI testing was done mostly in
112 patients who were > 50 years while MSI alone was done in patients between 30-50 years presenting
113 predominantly with non-metastatic malignancy. 22 malignancies were found in which NGS and
114 MSI was advised by treating physician.

115 The most common indication was carcinoma of unknown primary (CUP) and lung cancer
116 representing 26 % and 25% respectively. This was followed by colon cancer (9%), breast cancer
117 (8%).MSI testing was done solely as an only hotspot test in around 44% of patients, mostly those
118 with colon cancer. Inhouse targeted hotspot test was offered in 13 patients, mostly done in patients
119 with colon cancer. Majority of patients had metastatic disease. NGS testing was recommended in
120 first line of treatment after the diagnosis in majority of the patients. Actionable alterations were
121 detected in 31.8% of which only 17.2% patients received genotype-matched treatment. This was
122 most commonly done in first line treatment for lung cancer. Table 1

123

124

125

126 **Table 1: Demographics**

	NGS -FMI (N=192) %	MSI- AKU (N=162) %	NGS -AKU (N=13) %
Age (Yrs.)			
<30	9 (4.7%)	10 (6.2%)	0
30-50	45 (23.4%)	103 (63.6%)	5 (38.5%)
>50	138 (71.9%)	49 (30.2%)	8 (61.5%)
Sex			
Female	86 (44.8%)	60 (37.0%)	5 (38.5%)
Male	106 (55.2%)	102 (63.0%)	8 (61.5%)
Primary malignancy			
Bone cancer	2 (1.0%)	-	
Breast cancer	16 (8.3%)	-	1 (7.7%)
Cervical cancer	3 (1.6%)	-	
Colon cancer	19 (9.9%)	80 (49.4%)	10 (76.9%)
Esophageal cancer	3 (1.6%)	7 (4.3%)	
Gall Bladder cancer	4 (2.1%)	5 (3.1%)	
gastric cancer	1 (0.5%)	12 (7.4%)	
Head and Neck cancer	2 (1.0%)	-	
Kidney Cancer	1 (0.5%)	-	
Lung cancer	49 (25.5%)	-	
Melanoma	1 (0.5%)	-	1 (7.7%)
Ovarian cancer	4 (2.1%)	2 (1.2%)	
Pancreatic cancer	13 (6.8%)	7 (4.3%)	1 (7.7%)
Prostate cancer	4 (2.1%)	5 (3.1%)	
Rectal cancer	4 (2.1%)	36 (22.2%)	
Skin cancer	1 (0.5%)	-	
Soft Tissue sarcoma	5 (2.6%)	-	
Thyroid cancer	3 (1.6%)	-	
Unknown primary	50 (26.0%)	-	
Urothelial cancer	1 (0.5%)	-	
Uterine cancer	6 (3.1%)	7 (4.3%)	
Neuroendocrine Tumor	-	1 (0.6%)	

Stage			
Metastatic	189 (98.4%)	104 (64.2%)	13 (100%)
Non-metastatic	3 (1.6%)	58 (35.8%)	0
Line of treatment (At the time of NGS)			
First	187 (97.4%)	153 (94.4%)	13 (100%)
Second	5 (2.6%)	9 (5.6%)	0
MSI testing	183 (95.3%)		
MSI-H	6 (3.2%)	27 (16.7%)	-
MSS	177 (96.7%)	135 (83.3%)	-
Tumour mutational burden			
<10 Muts/Mb	123 (64.1%)	-	-
>10 Muts/Mb	23 (12.0%)	-	-
0 Muts/Mb	46 (24.0%)	-	-
Actional alteration	61 (31.8%)	-	3 (23.07%)
No Alteration (Wild type)	131 (68.2%)	-	10 (76.9%)
Genotype matched treatment			
N/A	3 (1.6%)	-	
No	156 (81.3%)	113 (69.7%)	12 (92.3)
Yes	33 (17.2%)	49 (30.2%)	1 (7.6%)
Line of treatment (first/second/third or beyond)			
First Line	17 (8.9%)	35 (21.6%)	1 (7.6%)
N/A	157 (81.8%)	-	-
Second line	18 (9.4%)	14 (8.6%)	-

127

128 GENOMIC LANDSCAPE

129 MSI testing

130 MSI testing was done as a part of Foundation one CDx panel and also as a targeted hotspot test
 131 via PCR at institute. Most common indication was colon cancer (49%) followed by rectal cancer

132 (22%) and gastric cancer (7%). In colon cancer, 28.7% patients are found to have MSI -H while
133 71.2% are MSS and most commonly performed in stage II colon cancer. In rectal cancer majority
134 of the patients were MSS (92%) and mostly done in metastatic disease. Matched treatment
135 according to instability testing was given in all patients with colon cancer. MSI testing in patients
136 other than colon cancer was done in metastatic presentation. Table 2

137 **Table 2: MSI testing MSI (N=162)**

Primary malignancy	MSI testing No. (%)	MSI-H No. (%)	MSS No. (%)	Matched treatment No. (%)
Colon cancer	80 (49.4%)	23 (28.7%)	57 (71.2%)	46 (93.9%)
Esophageal cancer	7 (4.3%)	1 (14.2%)	6 (85.7%)	2 (4.1%)
Gall Bladder cancer	5 (3.1%)	5 (100%)	0 (0%)	0 (0%)
Gastric cancer	12 (7.4%)	1 (8.3%)	11 (91.6%)	1 (2.0%)
Ovarian cancer	2 (1.2%)	0 (0%)	2 (100%)	0 (0%)
Pancreatic cancer	7 (4.3%)	0 (0%)	7 (100%)	0 (0%)
Prostate cancer	5 (3.1%)	0 (0%)	5 (100%)	0 (0%)
Rectal cancer	36 (22.2%)	1 (2.7%)	35 (97.2%)	0 (0%)
Uterine cancer	7 (4.3%)	1 (14.2%)	6 (85.7%)	0 (0%)
Neuroendocrine tumor	1 (0.6%)	0 (0%)	1 (100%)	0 (0%)

138

139 **Cancer types and molecular targets and implication on treatment.**


140 22 different cancers genomic profiling were studied. Most common were the Lung cancer,
141 carcinoma of unknown primary, breast and colon cancer. Each with different demographic details,
142 genomic alteration (either targetable or non-targetable), line of treatment and matched treatment

143 as per result. Most actionable alteration were detected in lung cancer. Mostly the patients had
144 upfront testing when diagnosed with metastatic disease.

145 49 patients with lung cancer, 50 with carcinoma of unknown primary, 16 with breast cancer, 92
146 patients with colon cancer underwent NGS (Foundation one) testing. In all cancer type mostly
147 patients were male expect those with breast cancer with age greater than 50 years. Most common
148 mutation detected in lung cancer was EGFR Exon 19 deletion (16.3%), KRAS- G12C
149 amplification (14.3%), ERBB amplification (8.2%) followed by EGFR L858R, CDK 4
150 amplification, BRAF. (Graph 1). Common mutation in carcinoma of unknown primary were
151 BRAF/ MYC amplification (8%), CDK-4 amplification (8%) followed by EGFR amplification,
152 NF-1 loss (6%). (Graph 2). In breast cancer, common mutation was PIK3CA amplification, PTEN
153 (18%) followed by BRCA 2 (12.5%) and BRCA 1 (6.3%) (Graph 3). And in colon cancer common
154 mutation detected were KRAS and TP53 (42.1%) followed by TP53 alone (26.3%). All the patients
155 were Microsatellite stable (MSS) with Tumor mutational burden (TMB) < 10 mut/Mb. Only 10.5%
156 of the patients were MSI-H in colon cancer. (Graph 4).


157 Actionable mutation was detected in 30%, 16%, 37% and 47% in lung, carcinoma of unknown
158 primary, breast cancer and colon cancer respectively. Genotype matched treatment was received
159 in 30%, 6%, 12.5% and 36% respectively. Most likely limitation for not receiving genotype
160 matched treatment was due to non – availability of drug and non-affordability.

161 Graph 1: Molecular Alteration detected in NGS – Lung cancer




162

163 Graph 2: Molecular Alteration detected in NGS- Carcinoma of Unknown Primary.



164


165 Graph 3: Molecular Alteration detected in NGS- Breast Cancer



166

167

168 Graph 4: Molecular Alteration detected in NGS- Breast Cancer



169

170 **Other cancer types:**

171 17 other different cancers genomic profiling were studied. No actionable mutation was detected in
172 majority of cancer. While in other cancers like esophageal cancer (3 patients), Gall bladder cancer
173 (4 patients), rectal cancer (4 patients), skin cancer (1 patient), thyroid cancer (3 patients) and
174 uterine cancer (6 patients), in which actionable alteration were detected but no genotype matched
175 treatment was given mainly due to non- availability of drugs. Table -3

176 **Table 3: Cancer and Alteration**

Cancer and Alteration	%
Pancreatic Cancer	
CDK4- amplification	8%
ERBB2- amplification	15%
KRAS- G12D	46%
MDM2- amplification	8%
NF1- rearrangement	8%
STK11- loss	8%

Cervical Cancer	
MET- amplification/ ARID1A- S11fs*91	33%
PIK3CA	33%
PIK3CA-	33%
Esophageal Cancer	
ARID1A- Y551fs*68	33%
CCND1- amplification	33%
ERBB2- amplification/ MYC- amplification	33%
Gall Bladder Cancer	
(PD-L1)- amplification/ (PD-L2)- amplification/ KRAS- amplification,	25%
EGFR- amplification-equivocal/ NF1- F2156L	25%
ERBB2-amplification-	50%
Ovarian Cancer	
RAD51B- R47*	25%
CBL- C381Y	25%
NF1- L190*/ MYC- amplification-equivocal/ TP53- R280*	25%
Prostate Cancer	
APC- F1954fs*16/ PIK3R1- T576del, rearrangement intron 7/ PTEN- loss	25%
AR- amplification/ CTNNB1- S45P- subclonal/ PTEN- loss/ RET- amplification	25%
MYC- amplification/ TMPRSS2- TMPRSS2-ERG fusion	25%
NF1- rearrangement intron 13	25%
Rectal Cancer	
KRAS- G12C	25%
NRAS- Q61K	25%
RNF43- R221fs*39	25%

Soft tissue sarcoma	
CDK4- amplification/ MDM2- amplification/	60%
EWSR1- EWSR1-ATF1 fusion	20%
PTEN- loss exons 3-9	20%
Thyroid cancer	
BRCA1- S1253fs*10/ AKT2- amplification/ AKT3- amplification-equivocal/ KEAP1- Y300*/ MTAP- loss exons 5-8	33%
NRAS- Q61R	33%
RET- M918T/ NF1- W221*	33%
Uterine cancer	
PIK3CA	50%
FBXW7- R479*/ PIK3CA-	17%
PIK3R1	17%

177

178 **Discussion:**

179 The success in drug interaction associated with genomic alteration have led to implementation of
180 NGS testing with the capability to sequence many genes for specific cancer in a short period of
181 time. In real world medical practice NGS panel testing ordered by oncologist increasingly but still
182 there is still controversy that whether molecular profiling is needed upfront in all the oncological
183 patients, this issue is still unresolved [9]. In 2020 NGS recommendation were published which
184 proposed that NGS testing must be focused on advanced cancer in which several molecular markers
185 are relevant for the initial treatment like colon cancer, lung cancer, melanoma, unknown primary
186 tumors [10]. Our current study have appraised the integration of NGS into clinical perspective of
187 patient care which can help in assessing therapeutic decision making among solid tumors.

188 Carcinoma of unknown primary always remains a unique challenge to the clinician as represented
189 as a heterogenous group of malignancies with distinct disease course and biology. Studies have
190 shown that progress in genomic profiling elaborate further insight into downstream pathways and
191 cellular system which further aid in subclassification into tumor origin that may sometime help as
192 a therapeutic target [11]. retrospective study on CUP revealed that most common actionable
193 alteration identified were PIK3CA, BRCA2, KRAS mutation, ERBB2 amplification and high
194 TMB. Median overall survival for those who treated with molecular guided therapy was 23.6
195 months as compared to historical data using conventional therapy [12]. In our study only 16% of
196 patients with carcinoma of unknown primary found to have actionable alteration and of which 6%
197 received molecular based treatment. Common mutations were BRAF/ MYC amplification, CDK-
198 4 amplification, EGFR amplification, NF-1 loss.

199 In lung cancer (specifically stage IV Non-small cell lung cancer (NSCLC), molecular testing
200 upfront before starting treatment has become standard of care. NGS though saves time and is cost-
201 effective when we compared with gene testing done sequentially but in our resource constraint
202 setting, we are obliged to get sequential testing in some patients. Presley et al. reported 29% of
203 actionable mutation via NGS testing [13] also report 61% targeted therapy usage [14]. Our study
204 revealed 55% of actionable target alteration which is similar to reported but only 30% of patients
205 received genotype matched treatment which is either due to unavailability of drug or non-
206 affordability. Furthermore, our study did not compare survival outcome between patients
207 undergoing NGS testing versus sequential molecular testing.

208 From the discovery of molecular biomarkers KRAS/NRAS in colon cancer with confers resistance
209 to anti EGFR therapy we have moved to different molecular subtype of metastatic colorectal cancer
210 with different treatment options. Therefore, molecular profiling became essential, and the
211 guideline recommends that all the patients with metastatic colorectal cancer must be tested for .
212 Our study also revealed that the most common mutation detected was KRAS/TP53 and 10% MSI-
213 H with is similar to reported in the studies [15].

214 Improved outcomes were shown in cancer particularly lung cancer, clinical trial screening or rare
215 cancer for making therapeutic decision association with NGS testing when it was performed
216 initially. Median PFS was found to be almost a year in cancer patients with a good performance
217 status and those with early in course of metastatic assessment as compared to those with rapidly
218 progressing tumors and with poor performance status.

219 NGS testing impact actually has some limitation that it only focuses on gene alteration but has not
220 taken into account the patient's general health and on the outcomes associated with test and also
221 improvement in survival has not been addressed clearly. Our study although limited in sample size
222 offers an overview of in which cancer subtype NGS is mostly ordered by oncologist. Our
223 observation strengthens the need of NGS in advanced cancer and the need for improving the
224 understanding of genomic drug association.

225 Our results show that the implementation of NGS analysis does support clinical decision making.
226 However, the results are applicable in small percentage of patients. For better compliance and
227 applicability, drug availability and cost of treatment need to be addressed.

228

229

230

231 **References**

- 232 1. Russnes HG, Navin N, Hicks J, Borresen-Dale AL. Insight into the heterogeneity of breast
233 cancer through next-generation sequencing. *J Clin Invest*. 2011 Oct;121(10):3810-8. doi:
234 10.1172/JCI57088. Epub 2011 Oct 3. PMID: 21965338; PMCID: PMC3195464.
- 235 2. US Food and Drug Administration. Table of pharmacogenetic associations. Silver Spring,
236 MD: US Food and Drug Administration; 2020.
- 237 3. Malapelle U, Vigliar E, Sgariglia R, Bellevicine C, Colarossi L, Vitale D, Pallante P,
238 Troncone G. Ion Torrent next-generation sequencing for routine identification of clinically
239 relevant mutations in colorectal cancer patients. *J Clin Pathol*. 2015 Jan;68(1):64-8. doi:
240 10.1136/jclinpath-2014-202691. Epub 2014 Nov 5. PMID: 25378536.
- 241 4. Levy SE, Boone BE. Next-Generation Sequencing Strategies. *Cold Spring Harb Perspect*
242 *Med*. 2019 Jul 1;9(7):a025791. doi: 10.1101/cshperspect.a025791. PMID: 30323017;
243 PMCID: PMC6601457.
- 244 5. Holt S, Bertelli G, Humphreys I, Valentine W, Durrani S, Pudney D, Rolles M, Moe M,
245 Khawaja S, Sharaiha Y, Brinkworth E, Whelan S, Jones S, Bennett H, Phillips CJ. A
246 decision impact, decision conflict and economic assessment of routine Oncotype DX
247 testing of 146 women with node-negative or pN1mi, ER-positive breast cancer in the U.K.

- 248 Br J Cancer. 2013 Jun 11;108(11):2250-8. doi: 10.1038/bjc.2013.207. Epub 2013 May 21.
249 PMID: 23695023; PMCID: PMC3681004.
- 250 6. Coquerelle S, Darlington M, Michel M, Durand M, Borget I, Baffert S, Marino P, Perrier
251 L, Durand-Zaleski I; NGSEco Group. Impact of Next Generation Sequencing on Clinical
252 Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to
253 Experimental Treatments. Value Health. 2020 Jul;23(7):898-906. doi:
254 10.1016/j.jval.2020.03.005. Epub 2020 Jul 18. PMID: 32762992.
- 255 7. Jones TE, Zou J, Tseng GC, Roy S, Bhargava R. The Utility of Next-Generation
256 Sequencing in Advanced Breast and Gynecologic Cancers. Am J Clin Pathol. 2021 Aug
257 4;156(3):455-460. doi: 10.1093/ajcp/aqaa256. PMID: 33728425.
- 258 8. Suh KJ, Kim SH, Kim YJ, Shin H, Kang E, Kim EK, Lee S, Woo JW, Na HY, Ahn S, Jang
259 BS, Kim IA, Park SY, Kim JH. Clinical Application of Next-Generation Sequencing in
260 Patients With Breast Cancer: Real-World Data. J Breast Cancer. 2022 Oct;25(5):366-378.
261 doi: 10.4048/jbc.2022.25.e30. Epub 2022 Jun 28. PMID: 35914747; PMCID:
262 PMC9629971.
- 263 9. Dienstmann R, Lonardi S. Is upfront full molecular profiling needed in all patients with
264 colorectal cancer in daily practice? Lancet Oncol. 2022 Sep;23(9):1129-1131. doi:
265 10.1016/S1470-2045(22)00035-3. PMID: 36055302.
- 266 10. Colomer R, Mondejar R, Romero-Laorden N, Alfranca A, Sanchez-Madrid F, Quintela-
267 Fandino M. When should we order a next generation sequencing test in a patient with
268 cancer? EClinicalMedicine. 2020 Jul 31;25:100487. doi: 10.1016/j.eclinm.2020.100487.
269 PMID: 32775973; PMCID: PMC7397394.

- 270 11. Oien KA. Pathologic evaluation of unknown primary cancer. *Semin Oncol.* 2009
271 Feb;36(1):8-37. doi: 10.1053/j.seminoncol.2008.10.009. PMID: 19179185.
- 272 12. Fusco MJ, Knepper TC, Balliu J, Del Cueto A, Laborde JM, Hooda SM, Brohl AS, Bui
273 MM, Hicks JK. Evaluation of Targeted Next-Generation Sequencing for the Management
274 of Patients Diagnosed with a Cancer of Unknown Primary. *Oncologist.* 2022 Feb
275 3;27(1):e9-e17. doi: 10.1093/oncolo/oyab014. PMID: 35305098; PMCID: PMC8842368.
- 276 13. Presley CJ, Tang D, Soulos PR, Chiang AC, Longtine JA, Adelson KB, Herbst RS, Zhu
277 W, Nussbaum NC, Sorg RA, Agarwala V, Abernethy AP, Gross CP. Association of Broad-
278 Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small
279 Cell Lung Cancer in the Community Oncology Setting. *JAMA.* 2018 Aug 7;320(5):469-
280 477. doi: 10.1001/jama.2018.9824. PMID: 30088010; PMCID: PMC6142984.
- 281 14. Al-Ahmadi A, Ardeshir-Larijani F, Fu P, Cao S, Lipka MB, Dowlati A, Bruno DS. Next
282 Generation Sequencing of Advanced Non-Small Cell Lung Cancer: Utilization Based on
283 Race and Impact on Survival. *Clin Lung Cancer.* 2021 Jan;22(1):16-22.e1. doi:
284 10.1016/j.clc.2020.08.004. Epub 2020 Sep 18. PMID: 33397584..
- 285 15. Bayle A, Basile D, Garinet S, Rance B, Laurent-Puig P, Blons H, Taieb J, Perkins G. Next-
286 Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers.
287 *Cancers (Basel).* 2021 Nov 17;13(22):5750. doi: 10.3390/cancers13225750. PMID:
288 34830904; PMCID: PMC8616114.